Latest Articles
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership - The Globe and Mail
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership The Globe and Mail
Published: June 16, 2026, 1:17 p.m.
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline - The Manila Times
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline The Manila Times
Published: June 11, 2026, 7:39 a.m.
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline - GlobeNewswire
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline GlobeNewswire
Published: June 11, 2026, 7:30 a.m.
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com UK
Published: May 21, 2026, 8:34 p.m.
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com
Published: May 21, 2026, 2:57 p.m.
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update BioSpace
Published: May 18, 2026, 1:17 a.m.
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart
Published: May 14, 2026, 4:30 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise
Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete - AD HOC NEWS
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete AD HOC NEWS
Published: May 14, 2026, 12:26 p.m.
Link copied to clipboard!